However, it is important to note that in our study, the association of NAFLD and clinically significant fibrosis with worsening of glycaemic control remained statistically significant even after adjusting for some important confounding factors at baseline, including the use of GLP-1 receptor agonists, SGLT-2 inhibitors or pioglitazone that may positively affect NAFLD (steatosis) and liver fibrosis. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.